<DOC>
	<DOCNO>NCT00774800</DOCNO>
	<brief_summary>Humalog Humulin-R ( recombinant human insulin ) Food Drug Administration ( FDA ) approve medication treatment diabetes mellitus . Recombinant human hyaluronidase PH20 ( rHuPH20 ) approve FDA use aid absorption dispersion injectable drug . In study , rHuPH20 co-administered Humalog Humulin-R order determine improve absorption insulin closely mimic body 's natural increase insulin response meal .</brief_summary>
	<brief_title>Phase II Pharmacokinetics Study Humalog Humulin-R With Without rHuPH20 Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Participants receive 4 intervention order . Dose-finding visit conduct identify appropriate dose Humalog Humulin-R. For Humalog dose-finding visit , total 24 U rHuPH20 inject SC per unit Humalog , correspond mass concentration 18.2 microgram per milliliter ( μg/mL ) rHuPH20 ( final concentration 91 U/mL Humalog ) . For Humulin-R dose-finding visit , total 24 U rHuPH20 inject SC per unit Humulin-R , correspond mass concentration 20.0 μg/mL rHuPH20 ( final concentration 100 U/mL Humulin-R ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Male female age 18 65 year , inclusive . Females childbearing potential must use standard effective mean birth control duration study . Participants Type 1 diabetes mellitus treat insulin great equal 12 month . Body mass index ( BMI ) 18.0 29.0 kilogram per meter square ( kg/m^2 ) , inclusive . Glycosylated hemoglobin A1c ( HbA1c ) less equal 10 % base local laboratory result . Fasting Cpeptide le 0.6 nanogram per milliliter ( ng/mL ) . Current treatment insulin le 1.2 unit per kilogram per day ( U/kg/day ) . Participants good general health base medical history physical examination , without medical condition might prevent completion study drug injection assessment require protocol . Known suspected allergy component study drug trial . Previous enrollment trial . A participant proliferative retinopathy maculopathy , and/or severe neuropathy , particular autonomic neuropathy , judge Investigator . Clinically significant ( judged Investigator ) active disease gastrointestinal , cardiovascular ( include history arrhythmia conduction delay electrocardiogram [ ECG ] ) , hepatic , neurological , renal , genitourinary , hematological system , uncontrolled hypertension ( diastolic blood pressure great equal 100 millimeter mercury [ mmHg ] and/or systolic blood pressure great equal 160 mmHg 5 minute supine position ) . History illness disease opinion Investigator might confound result trial pose additional risk administer study drug participant . Clinically significant finding ( judged Investigator ) routine laboratory data , include anemia hemoglobin less low limit normal screen . Use drug may interfere interpretation trial result know cause clinically relevant interference insulin action , glucose utilization , recovery hypoglycemia . Recurrent major hypoglycemia hypoglycemic unawareness , judge Investigator . Current addiction alcohol substance abuse determine Investigator . Blood donation ( &gt; 500 milliliter [ mL ] ) within 9 week prior first day dose study . Pregnancy , breastfeeding , intention become pregnant , use adequate contraceptive measure ( adequate contraceptive measure consist sterilization , intrauterine device [ IUD ] , oral injectable contraceptive barrier method ) . Mental incapacity , unwillingness , language barrier preclude adequate understanding cooperation . Symptomatic gastroparesis . History evidence use tobacco nicotinecontaining product within 6 month screen screen quantitative urine nicotine concentration &gt; 50 ng/mL . Receipt investigational drug within 4 week first day dose study . Any condition ( intrinsic extrinsic ) judgment Investigator interfere trial participation evaluation data .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Recombinant Hyaluronidase</keyword>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>Humalog</keyword>
	<keyword>Humulin R</keyword>
	<keyword>rHuPH20</keyword>
	<keyword>Hylenex</keyword>
</DOC>